At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,645 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Atopic Dermatitis. Completed, enrolled 1,645 participants across 185 sites in 19 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis. Participants were enrolled in this study from the originating studies (JAHL, JAHM, JAIY) or were directly enrolled in the open-label arm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesArgentina, Australia, Austria, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Mexico, Poland, Russia, South Korea, Spain, Switzerland, Taiwan
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartMar 2018
Primary CompletionSep 2020
Study CompletionJul 2023
TodayJul 2026
First PostedNov 7, 2017
Enrollment StartMar 28, 2018
Primary CompletionSep 21, 2020
Study CompletionJul 12, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.7 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally